华润医药披露2026年中期业绩及早期创新药进展，短线预期差不足

China Resources Pharmaceutical Group Limited (3320.HK) reported interim results for the six months ended June 30, 2026, highlighting steady revenue growth, resilient profitability and continued progress across its pharmaceutical innovation and strategic growth initiatives.
Financial Performance
China Resources Pharmaceutical Group reported a 26.1% year-over-year decline in finance income to RMB200.5 million in H1 2026 from RMB271.3 million in the prior-year period.
Despite the decline in finance income, the company's bottom line increased, with first-half earnings rising to RMB2.186 billion, or RMB0.35 per share, from RMB2.077 billion, or RMB0.33 per share, in the same period last year.
Total revenue increased 2.0% year over year to RMB134.457 billion from RMB131.866 billion, supported by growth across its pharmaceutical and other businesses.
The company reported profit of approximately RMB5.02 billion, compared with RMB5.05 billion a year earlier, while gross profit edged up to RMB21.53 billion from RMB21.51 billion, with the overall gross profit margin at 16.0%.
The Board declared an interim dividend of RMB0.087 per share, representing an approximately 21% increase from RMB0.072 per share in the prior-year period.
China Resources Pharmaceutical Group Limited Bottom Line Climbs In H1, with earnings rising to RMB2.186 billion from RMB2.077 billion a year earlier, while revenue increased 2.0% to RMB134.457 billion.
Pipeline And Innovation Progress
The company continued to advance its innovative drug pipeline across rare diseases, diabetes, oncology, depression, ophthalmology and autoimmune diseases.
Its Class 1 innovative antidepressant entered a Phase IIb clinical study, while DC6001, a candidate for macular degeneration, received clinical trial approvals in China and the U.S. and obtained FDA Pediatric Rare Disease Designation.
DC7001A, a Class 1 candidate for systemic lupus erythematosus, was filed simultaneously in China and the U.S.
The company's human coagulation factor IX received clinical trial approval from China's NMPA, while human von Willebrand factor received another NMPA clinical trial approval in July 2026.
Strategic Expansion And Growth InitiativesChina Resources Pharmaceutical continued to expand through acquisitions and internal restructuring, including the acquisition of Dong-E-E-Jiao Jilin and CR Double-Crane's acquisition of Nanjing Xinbai.
The company is also building a second growth engine through synthetic biology, with Shenzhou Biology & Technology expanding production and commercialization capabilities.
Its coenzyme Q10 business reached the top global market position, while a 1,000-tonne annual purification and refining production line was put into operation.
Cash And Financial Position
As of June 30, 2026, China Resources Pharmaceutical had approximately RMB15.62 billion in cash and cash equivalents, compared with RMB15.84 billion at the end of 2025.
Net cash generated from operating activities totaled approximately RMB1.42 billion during the first half of 2026, compared with RMB1.53 billion in the prior-year period.
3320.HK has traded between $4.22 and $6.53 over the past year. The stock closed Monday's trading at $4.70, down 2.18%.
For comments and feedback contact: editorial@rttnews.com
Business News
August 21, 2026 14:42 ET The minutes of the latest policy meeting of the Federal Reserve, housing market data and manufacturing sector survey results were the main news for the U.S. economy this week. In Europe, inflation data from the U.K. was the highlight, while consumer price data from Japan drew attention in Asia.